A physician-formulated, clinically informed approach to cycle, ovarian-function, and insulin-sensitivity support.
Polyendocrine metabolic ovarian syndrome, PMOS, formerly known as PCOS, affects roughly one in five women of reproductive age. It’s marked by irregular cycles, elevated androgen signs, and ovarian changes visible on ultrasound. For many women, insulin resistance underlies much of that picture, and that’s where the nutrient inositol enters the conversation.
Inositol shows up in the body in several forms, but two matter most here: myo-inositol (MI) and D-chiro-inositol (DCI). They do different jobs in different tissues. The ratio between them, not just the total amount, is central to how Balance is designed.
Why the ratio is the whole point
Healthy ovarian follicular fluid contains MI and DCI in roughly a 40:1 ratio. That’s also the ratio most commonly studied in PMOS research, and the one Balance formulates to. Myo-inositol predominates (the “40”), most associated with ovarian function and egg quality; D-chiro-inositol complements it (the “1”) on the metabolic side. In practice, that’s 2,000 mg of myo-inositol paired with 50 mg of D-chiro-inositol, a precise 40:1, not myo-inositol alone or an arbitrary blend.
What the evidence shows
Among nutritional approaches for PMOS, inositol has one of the most robust evidence bases. While the research continues to evolve, we present the current evidence transparently and with appropriate context.
Concluded inositol is an effective and safe option in PMOS, increasing the likelihood of a regular menstrual cycle versus placebo and improving measures like BMI, testosterone, and glucose, with non-inferiority in most outcomes compared to the standard treatment, metformin.
Found the combination effective at regularizing menstrual cycles and improving insulin resistance in young women with PMOS.
Both improved insulin sensitivity and normalized the menstrual cycle in about half of participants, with inositol generally better tolerated.
Took a more cautious view, suggesting benefit of MI or DCI for some metabolic measures and potential benefit of DCI for ovulation, while noting that overall evidence remains limited and treatment decisions should be shared with a clinician.
The honest summaryInositol is one of the best-studied and best-tolerated nutritional options for this condition, with consistent signals around cycle regularity and insulin sensitivity. Balance formulates to the ratio and to the evidence, and it’s nutritional support, not a treatment or cure.
A deliberately narrow formula
Balance is one active formula, the 40:1 inositol blend, rather than a long list of trace vitamins and minerals. That focus is the point: a clinically meaningful amount of the nutrient with real evidence behind it, and nothing else along for the ride.
- Third-party tested
- GMP-certified
- Vegan
- No added sugar
- FSA/HSA eligible
This formula is designed to support cycle regularity, ovarian function, and insulin sensitivity as part of a nutritional approach to hormonal health. It does not treat, cure, or manage PMOS as a medical condition, and it is not a substitute for your doctor’s care. PMOS is best managed with a clinician who knows your history.
You may still see “PCOS” referenced on some of our pages while our language catches up to the new terminology. The formula hasn’t changed; the name behind the science has.
Supplement facts
* Percent Daily Values are based on a 2,000 calorie diet. ** Daily Value not established.
Other ingredients: maltitol, erythritol, water, pectin, citric acid, potassium citrate, natural flavors and added colors.
References
- Greff D, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of RCTs. Reprod Biol Endocrinol. 2023;21(1):10.
- Fitz V, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab. 2024;109(6):1630-1655.
- Kachhawa G, et al. Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with PCOS. Int J Gynaecol Obstet. 2021;158(2):278-284.
- Fruzzetti F, et al. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with PCOS. Gynecol Endocrinol. 2017;33(1):39-42.
- Alesi S, et al. Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome. Adv Nutr. 2022;13(4):1243-1266.
- DiNicolantonio JJ, O’Keefe JH. Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart. 2022;9(1):e001989.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Physician-formulated for nutritional support.
